Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients.

[1]  N. Brünner,et al.  Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  N. Brünner,et al.  The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion , 1995 .

[3]  N. Brünner,et al.  The plasminogen activation system and its role in lung cancer. A review. , 1995, Lung cancer.

[4]  N. E. Hansen,et al.  The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria , 1995, British journal of haematology.

[5]  N. Brünner,et al.  A cleaved form of the receptor for urokinase‐type plasminogen activator in invasive transplanted human and murine tumors , 1994, International journal of cancer.

[6]  N. Brünner,et al.  Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. , 1994, Cancer research.

[7]  M. Duffy,et al.  Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer , 1994, The Lancet.

[8]  H. Verspaget,et al.  Urokinase receptor and colorectal cancer survival , 1994, The Lancet.

[9]  C. V. D. van de Velde,et al.  Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. , 1994, Cancer research.

[10]  H. Nekarda,et al.  Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer , 1994, The Lancet.

[11]  H. Nielsen,et al.  Quantitation of the receptor for urokinase plasminogen activator by enzyme-linked immunosorbent assay. , 1994, Journal of immunological methods.

[12]  F. Jänicke,et al.  A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. , 1993, The Journal of clinical investigation.

[13]  J. Gris,et al.  Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas. , 1993, Chest.

[14]  N. Brünner,et al.  High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. , 1993, Cancer research.

[15]  V. Ellis,et al.  The Urokinase Receptor: Involvement in Cell Surface Proteolysis and Cancer Invasion , 1992, Annals of the New York Academy of Sciences.

[16]  J. Foekens,et al.  Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. , 1992, Cancer research.

[17]  L. Lund,et al.  Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. , 1992, The Journal of biological chemistry.

[18]  N. E. Hansen,et al.  A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria. , 1992, European journal of biochemistry.

[19]  S. Moestrup,et al.  Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. , 1992, The Journal of biological chemistry.

[20]  E. Appella,et al.  Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. , 1992, The Journal of biological chemistry.

[21]  J. Riordan,et al.  Membrane proteins with soluble counterparts: role of proteolysis in the release of transmembrane proteins. , 1991, Biochemistry.

[22]  M. Ploug,et al.  Cell‐induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2‐terminal domain of the urokinase receptor , 1991, FEBS letters.

[23]  F. Blasi,et al.  The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. , 1991, The Journal of biological chemistry.

[24]  L. Liotta,et al.  Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation , 1991, Cell.

[25]  F. Blasi,et al.  Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. , 1991, The Journal of biological chemistry.

[26]  M. Duffy,et al.  Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. , 1990, Cancer research.

[27]  E. Appella,et al.  The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. , 1990, The Journal of biological chemistry.

[28]  M. Cubellis,et al.  Receptor‐mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI‐1. , 1990, The EMBO journal.

[29]  E. Appella,et al.  Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. , 1990, The EMBO journal.

[30]  D. Belin,et al.  Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas. , 1987, Cancer research.

[31]  F. Blasi,et al.  Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors , 1987, The Journal of cell biology.

[32]  C. Bordier.  Phase separation of integral membrane proteins in Triton X-114 solution. , 1981, The Journal of biological chemistry.

[33]  P. Kristensen,et al.  The Plasminogen Activation System in Human Colon Cancer : Messenger RNA for the Inhibitor PAI-1 Is Located in Endothelial Cells in the Tumor , 2006 .

[34]  N. Brünner,et al.  Urokinase-type receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies , 1994 .

[35]  N. Brünner,et al.  Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. , 1994, Cancer research.

[36]  S. Kitada,et al.  The content of urokinase-type plasminogen activator and tumor recurrence in superficial bladder cancer. , 1994, The Journal of urology.

[37]  G. Murphy,et al.  Physiological mechanisms for metalloproteinase activation. , 1992, Matrix (Stuttgart, Germany). Supplement.

[38]  A. Harris,et al.  Urokinase receptors in lung cancer and normal lung. , 1990, Anticancer Research.

[39]  K. Danø,et al.  Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.